Sign in
Stories
BMS Showcases Diverse Approaches in Multiple Myeloma Therapy
Share
Advancements in Cancer Treatment and Mar...
Advancements in Cell Therapies and Sickl...
Advancements in Lymphoma Treatments
AB-2100 Phase 1/2 Trial Initiated
Advancing CD70 Targeted Cancer Treatment...
Affini-T Therapeutics at J.P. Morgan Hea...
Overview
API
Bristol Myers Squibb (BMS) showcased diverse approaches to address unmet needs in multiple myeloma therapy at ASH 2023, presenting updated results from its pipeline. The company highlighted three programs including GPRC5D CAR T, novel CELMoD agent mezigdomide, and bispecific T cell engager alnuctamab PRINCETON. BMS also announced plans for a Phase 2 trial of BMS-986393 in patients with RRMM exposed to four or more classes of therapy, and emphasized its commitment to developing tailored treatment approaches through its protein degradation research platform.
Ask a question
How could the success of BMS's programs in multiple myeloma therapy influence the broader healthcare industry?
How might the diverse treatment approaches presented by BMS impact the landscape of multiple myeloma therapy?
What are the potential implications of BMS's commitment to developing tailored treatment approaches for multiple myeloma?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage